BRPI0711901A2 - Composições e métodos para a liberação de oxigênio - Google Patents

Composições e métodos para a liberação de oxigênio Download PDF

Info

Publication number
BRPI0711901A2
BRPI0711901A2 BRPI0711901-1A BRPI0711901A BRPI0711901A2 BR PI0711901 A2 BRPI0711901 A2 BR PI0711901A2 BR PI0711901 A BRPI0711901 A BR PI0711901A BR PI0711901 A2 BRPI0711901 A2 BR PI0711901A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
release
nox proteins
nox
Prior art date
Application number
BRPI0711901-1A
Other languages
English (en)
Inventor
P.L. Cary Stephen
M. Boon Elizabeth
Weinert Emily
A. Winger Jonathan
A. Marletta Michgael
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of BRPI0711901A2 publication Critical patent/BRPI0711901A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA A LIBERAÇçO DE OXIGÊNIO. Proteínas H-NOX são mutadas para exibir propriedades cinéticas e termodinâmicas aumentadas ou ideais para liberação sangüínea de gás O~2~. As proteínas H-NOX projetadas compreendem mutações que transmitem ligação de ligante de O~2~ ou NO alterada em relação ao domínio de H-NOX do tipo selvagem correspondente, e são operacionais como transportadores sangúíneos de gás O~2~ em mamíferos fisiologicamente compatíveis. A invenção também fornece composições farmacêuticas, kits e métodos que utilizam proteínas H-NOX do tipo selvagem ou mutantes para o tratamento de qualquer condição para a qual a liberação de O~2~ seja benéfica.
BRPI0711901-1A 2006-05-22 2007-05-21 Composições e métodos para a liberação de oxigênio BRPI0711901A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
US60/921.505 2006-05-22
PCT/US2007/012184 WO2007139791A2 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of oxygen

Publications (1)

Publication Number Publication Date
BRPI0711901A2 true BRPI0711901A2 (pt) 2012-03-06

Family

ID=38779160

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0711901-1A BRPI0711901A2 (pt) 2006-05-22 2007-05-21 Composições e métodos para a liberação de oxigênio
BRPI0711767A BRPI0711767B8 (pt) 2006-05-22 2007-05-21 composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0711767A BRPI0711767B8 (pt) 2006-05-22 2007-05-21 composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante

Country Status (13)

Country Link
US (7) US8404631B2 (pt)
EP (7) EP2463295A1 (pt)
JP (5) JP5698905B2 (pt)
CN (5) CN101495134B (pt)
AU (2) AU2007268052B2 (pt)
BR (2) BRPI0711901A2 (pt)
CA (2) CA2653101C (pt)
DK (4) DK2040740T3 (pt)
ES (4) ES2525226T3 (pt)
HK (1) HK1129688A1 (pt)
IN (2) IN2013MN00601A (pt)
NZ (4) NZ594457A (pt)
WO (2) WO2007139791A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711901A2 (pt) 2006-05-22 2012-03-06 The Regents Of The University Of California Composições e métodos para a liberação de oxigênio
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
WO2014107171A1 (en) * 2013-01-07 2014-07-10 Omniox, Inc. Polymeric forms of h-nox proteins
BR112017019862A2 (pt) * 2015-03-17 2018-05-29 Omniox Inc modulação de imunidade de tumor através de liberaçâo de o2 mediada por proteína
DK3416673T3 (da) 2016-02-16 2023-01-23 Omniox Inc Modulation af hypoxi associeret med slagtilfælde
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
EP3836911A1 (en) 2018-08-15 2021-06-23 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
KR20220085796A (ko) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
IL297327A (en) 2020-05-01 2022-12-01 Gilead Sciences Inc 4,2-deoxypyrimidine compounds that inhibit cd73
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
WO1995027040A1 (en) * 1994-04-01 1995-10-12 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
AU735799C (en) 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
AU750295B2 (en) 1997-05-02 2002-07-11 Baxter Biotech Technology S.A.R.L. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
EP1250155B1 (en) * 1999-12-22 2008-04-16 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
JP2004529603A (ja) * 2000-06-29 2004-09-30 インサイト・ゲノミックス・インコーポレイテッド アデニリルシクラーゼ及びグアニリルシクラーゼ
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
BRPI0711901A2 (pt) * 2006-05-22 2012-03-06 The Regents Of The University Of California Composições e métodos para a liberação de oxigênio

Also Published As

Publication number Publication date
BRPI0711767A2 (pt) 2012-01-10
EP2463296A1 (en) 2012-06-13
US20150266931A1 (en) 2015-09-24
AU2007268028B2 (en) 2013-03-14
JP2015007108A (ja) 2015-01-15
JP2014224156A (ja) 2014-12-04
JP6458070B2 (ja) 2019-01-23
ES2610653T3 (es) 2017-04-28
NZ594457A (en) 2013-06-28
CN101495134B (zh) 2016-08-03
US20150376250A1 (en) 2015-12-31
NZ573004A (en) 2012-06-29
EP2040740A2 (en) 2009-04-01
DK2032156T3 (da) 2013-02-18
US9493526B2 (en) 2016-11-15
JP2017137337A (ja) 2017-08-10
JP2009538133A (ja) 2009-11-05
US8404632B2 (en) 2013-03-26
NZ573003A (en) 2012-06-29
DK2463294T3 (en) 2017-01-16
EP2463295A1 (en) 2012-06-13
EP2040740A4 (en) 2009-10-21
EP2463294B1 (en) 2016-10-19
ES2611157T3 (es) 2017-05-05
IN2013MN00601A (pt) 2015-06-12
EP2032156B1 (en) 2012-11-21
EP2463297A1 (en) 2012-06-13
CN101495506B (zh) 2016-08-10
US9493527B2 (en) 2016-11-15
EP2474554A2 (en) 2012-07-11
CA2653101C (en) 2016-12-13
US20100266673A1 (en) 2010-10-21
WO2007139791A3 (en) 2008-05-02
AU2007268052B2 (en) 2013-07-04
WO2007139767A2 (en) 2007-12-06
EP2474554A3 (en) 2012-10-03
CN104689300A (zh) 2015-06-10
CN101495506A (zh) 2009-07-29
WO2007139791A2 (en) 2007-12-06
CN101495134A (zh) 2009-07-29
JP6118772B2 (ja) 2017-04-19
JP5698906B2 (ja) 2015-04-08
CA2653080A1 (en) 2007-12-06
AU2007268028A1 (en) 2007-12-06
US10202428B2 (en) 2019-02-12
JP2009538134A (ja) 2009-11-05
EP2032156A2 (en) 2009-03-11
US8404631B2 (en) 2013-03-26
CN106075388B (zh) 2021-06-29
EP2463297B1 (en) 2016-10-19
CA2653080C (en) 2019-02-12
US20170267732A1 (en) 2017-09-21
ES2399662T3 (es) 2013-04-02
WO2007139767A3 (en) 2008-02-07
JP6118296B2 (ja) 2017-04-19
US20100285104A1 (en) 2010-11-11
JP5698905B2 (ja) 2015-04-08
EP2040740B1 (en) 2014-09-03
HK1129688A1 (en) 2009-12-04
US20130288970A1 (en) 2013-10-31
IN2013MN00600A (pt) 2015-06-12
EP2032156A4 (en) 2009-11-11
AU2007268052A1 (en) 2007-12-06
CA2653101A1 (en) 2007-12-06
CN106075388A (zh) 2016-11-09
US20130289252A1 (en) 2013-10-31
NZ594456A (en) 2013-06-28
CN108273040A (zh) 2018-07-13
DK2040740T3 (en) 2014-12-01
BRPI0711767B1 (pt) 2018-05-15
DK2463297T3 (en) 2017-01-09
BRPI0711767B8 (pt) 2021-05-25
ES2525226T3 (es) 2014-12-19
CN104689300B (zh) 2018-06-05
EP2463294A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
BRPI0711901A2 (pt) Composições e métodos para a liberação de oxigênio
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
BR112012012160A2 (pt) material e métodos para tratar ou prevenir doenças associadas ao her-3
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
EP2679234A3 (en) Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
BRPI0821165B8 (pt) uso de uma composição
CR20110470A (es) Proteínas de union a il-17
EA200800667A1 (ru) Аптамеры, связывающие тромбин с высокой аффинностью
PH12014502419A1 (en) Specific binding proteins and uses thereof
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
MX2009008926A (es) Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2008136865A3 (en) (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
EA201400526A1 (ru) Смесь связанного триптофана в составе пептидов и связанного триптофана в составе полипептидов
MY162484A (en) Phosphate adsorbent
WO2010008491A3 (en) Lactose compositions with decreased lactose content
ATE510907T1 (de) Adenovirus mit mutationen in der domäne des e3- 19k-proteins zur retention im endoplasmatischen retikulum und verwendung in der krebsbehandlung
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
MY158310A (en) Prevention and treatment of allergic diarrhoea
MX2012004622A (es) Adyuvante para vacunas, vacunas que lo comprenden y usos.
CL2008001719A1 (es) Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements